Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
The price of Travere Therapeutics Inc (NASDAQ: TVTX) closed at $15.02 in the last session, down -2.34% from day before closing price of $15.38. In other words, the price has decreased by -$2.34 from its previous closing price. On the day, 1.89 million shares were traded.
Ratios:
We take a closer look at TVTX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 2.03 and its Current Ratio is at 2.05. In the meantime, Its Debt-to-Equity ratio is 12.20 whereas as Long-Term Debt/Eq ratio is at 9.94.
On October 21, 2024, Wells Fargo Upgraded its rating to Overweight which previously was Equal Weight and also upped its target price recommendation from $9 to $27.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on May 05 ’25 when Cline Christopher R. sold 1,784 shares for $21.05 per share. The transaction valued at 37,553 led to the insider holds 93,126 shares of the business.
Dube Eric M sold 18,924 shares of TVTX for $398,350 on May 05 ’25. The CHIEF EXECUTIVE OFFICER now owns 419,173 shares after completing the transaction at $21.05 per share. On May 05 ’25, another insider, Heerma Peter, who serves as the CHIEF COMMERCIAL OFFICER of the company, sold 1,771 shares for $21.05 each. As a result, the insider received 37,280 and left with 128,215 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 4.88 while its Price-to-Book (P/B) ratio in mrq is 40.63.
Stock Price History:
Over the past 52 weeks, TVTX has reached a high of $25.29, while it has fallen to a 52-week low of $6.79. The 50-Day Moving Average of the stock is -15.90%, while the 200-Day Moving Average is calculated to be -13.42%.
Shares Statistics:
A total of 88.79M shares are outstanding, with a floating share count of 87.50M. Insiders hold about 1.54% of the company’s shares, while institutions hold 112.64% stake in the company.
Earnings Estimates
Current recommendations for the stock of the company come from 8.0 analysts. The consensus estimate for the next quarter is -$0.06, with high estimates of $0.08 and low estimates of -$0.17.
Analysts are recommending an EPS of between $0.29 and -$0.82 for the fiscal current year, implying an average EPS of -$0.24. EPS for the following year is $1.33, with 10.0 analysts recommending between $2.38 and $0.22.
Revenue Estimates
According to 12 analysts, the current quarter’s revenue is expected to be $101.49M. It ranges from a high estimate of $114.4M to a low estimate of $77.76M. As of the current estimate, Travere Therapeutics Inc’s year-ago sales were $54.12MFor the next quarter, 12 analysts are estimating revenue of $100.17M. There is a high estimate of $112.26M for the next quarter, whereas the lowest estimate is $90.54M.
A total of 14 analysts have provided revenue estimates for TVTX’s current fiscal year. The highest revenue estimate was $444.38M, while the lowest revenue estimate was $333.83M, resulting in an average revenue estimate of $397.34M. In the same quarter a year ago, actual revenue was $233.18MBased on 14 analysts’ estimates, the company’s revenue will be $568M in the next fiscal year. The high estimate is $795.9M and the low estimate is $450.21M.
